Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Research & Development: 2017-2024

Historic Research & Development for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $506.5 million.

  • BridgeBio Pharma's Research & Development fell 6.29% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.9 million, marking a year-over-year decrease of 7.99%. This contributed to the annual value of $506.5 million for FY2024, which is 11.14% up from last year.
  • As of FY2024, BridgeBio Pharma's Research & Development stood at $506.5 million, which was up 11.14% from $455.7 million recorded in FY2023.
  • BridgeBio Pharma's Research & Development's 5-year high stood at $506.5 million during FY2024, with a 5-year trough of $337.0 million in FY2020.
  • In the last 3 years, BridgeBio Pharma's Research & Development had a median value of $455.7 million in 2023 and averaged $453.9 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Research & Development spiked by 60.54% in 2020, and later fell by 11.43% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Research & Development stood at $337.0 million in 2020, then spiked by 33.82% to $451.0 million in 2021, then declined by 11.43% to $399.5 million in 2022, then climbed by 14.08% to $455.7 million in 2023, then rose by 11.14% to $506.5 million in 2024.